TrialCancer chemotherapy and pharmacology2015

Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma.

N Yamazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.